Pharmacokinetic–pharmacodynamic (dipeptidyl peptidase‐4 inhibition) model to support dose rationale in diabetes patients, including those with renal impairment, for once‐weekly administered omarigliptin - Jain, Lokesh; Chain, Anne S.Y.; Tatosian, Daniel A.; Hing, Jeremy; Passarell, Julie A.; Kauh, Eunkyung A.; Lai, Eseng (British journal of clinical pharmacology, 2019)
Keywords: Blood Glucose - analysis; Clinical Trials as Topic; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Dipeptidyl Peptidase 4 - blood; dipeptidyl peptidase‐4 inhibitor; Dipeptidyl-Peptidase IV Inhibitors - administration & dosage; Dipeptidyl-Peptidase IV Inhibitors - blood; Dipeptidyl-Peptidase IV Inhibitors - therapeutic use; Dose-Response Relationship, Drug; Drug Administration Schedule; Heterocyclic Compounds, 2-Ring - administration & dosage; Heterocyclic Compounds, 2-Ring - blood; Heterocyclic Compounds, 2-Ring - therapeutic use; Humans; Hypoglycemic Agents - administration & dosage; Hypoglycemic Agents - blood; Hypoglycemic Agents - therapeutic use; Kidney Failure, Chronic - blood; Kidney Failure, Chronic - complications; Kidney Failure, Chronic - drug therapy; Models, Biological; omarigliptin; Original; population pharmacodynamics; population pharmacokinetics; Pyrans - administration & dosage; Pyrans - blood; Pyrans - therapeutic use; Renal Insufficiency - blood; Renal Insufficiency - complications; Renal Insufficiency - drug therapy; type 2 diabetes mellitus; type 2 diabetes mellitus; dipeptidyl peptidase-4 inhibitor; population pharmacodynamics; omarigliptin; population pharmacokinetics